<!DOCTYPE html>
<!--[if IE 9]><html lang="en-US" class="no-js ie-9"> <![endif]-->
<!--[if gt IE 9]><!--> <html lang="en-US" class="no-js"><!--<![endif]-->
<head>
<meta charset="UTF-8">
<meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=0">
<meta http-equiv="X-UA-Compatible" content="IE=edge">
<title>Pediatric Exclusivity for Biologics | MoFo Life Sciences</title>
<meta name="description" itemprop="description" content>
<meta name="description" itemprop="keywords" content>
<link rel="canonical" href="https://lifesciences.mofo.com/topics/pediatric-exclusivity-for-biologics.html">
<link rel="stylesheet" id="validate-engine-css-css" href="css/blog-validationEngine.jquery.css" type="text/css" media="all">
<link rel="stylesheet" id="fontello-css" href="css/blog-embedded.css" type="text/css" media="all">
<link rel="stylesheet" id="mofo-fonts-css" href="css/blog-fonts.css" type="text/css" media="all">
<link rel="stylesheet" id="child-normalize-css" href="css/blog-normalize.css" type="text/css" media="all">
<link rel="stylesheet" id="child-foundation-css" href="css/blog-foundation.css" type="text/css" media="all">
<link rel="stylesheet" id="child-style-css" href="css/blog-style.css" type="text/css" media="all">
<link rel="stylesheet" id="child-jetpack-css" href="css/blog-jetpack.css" type="text/css" media="all">
<link rel="stylesheet" href="css/blog-custom-style.css" type="text/css" media="all">
<link rel="stylesheet" href="css/blog-print.css" type="text/css" media="all">
<link rel="stylesheet" href="css/blog-simple-nav.css" type="text/css" media="all">
<link rel="shortcut icon" href="https://media2.mofo.com/designimages/mofo-favicon-blue-180x180-2018.png" type="image/icon">
<link rel="shortcut icon" type="image/vnd.microsoft.icon" href="favicon.ico">
<link rel="icon" href="favicon.ico" type="image/icon">
<link rel="apple-touch-icon" type="image/png" href="https://media2.mofo.com/designimages/mofo-favicon-blue-180x180-2018.png"><!-- iPhone -->
<link rel="apple-touch-icon" type="image/png" sizes="72x72" href="https://media2.mofo.com/designimages/mofo-favicon-blue-180x180-2018.png"><!-- iPad -->
<link rel="apple-touch-icon" type="image/png" sizes="114x114" href="https://media2.mofo.com/designimages/mofo-favicon-blue-180x180-2018.png"><!-- iPhone4 -->
<link rel="stylesheet" href="css/jquery-ui.css">


    <!-- Google Tag Manager -->
    <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
    new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
    j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
    'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
    })(window,document,'script','dataLayer','GTM-T8Z9VLF');</script>
    <!-- End Google Tag Manager -->


<script defer src="js/all.js" crossorigin="anonymous"></script>

<!-- Jetpack Open Graph Tags -->
<meta property="og:type" content="website">
<meta property="og:title" content="Pediatric Exclusivity for Biologics">


																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																				<meta property="og:description" content="The+U.S.+Food+and+Drug+Administration%26rsquo%3Bs+six-month+pediatric+exclusivity+rules+that+apply+to+drugs+also+largely+apply+to+biologics+%28albeit+with+certain+distinctions%29%2C+which+may+become+a+valuable+life+cycle+management+strategy+for+biopharmaceutical+companies+%28hereinafter+%26ldquo%3BSponsors%26rdquo%3B%29+in+addition+to+patent+exclusionary+rights.%0A%0AAt+the">
<meta property="og:url" content="https://lifesciences.mofo.com/topics/pediatric-exclusivity-for-biologics.html">
<meta property="og:site_name" content="MoFo Life Sciences">
<meta property="og:image" content="https://media2.mofo.com/images/mofolifesciences-intellectual-property.jpg">
<meta property="og:locale" content="en_US">



<style>
.svg-inline--fa {

    /*height: .8em;*/

    }
.svg-inline--fa {
    width: .475em;
}
 .sd-content a.nc-facebook-circled{
     color: #3b5998;
     font-size: 30px;
     }
     .sd-content a.nc-linkedin-circled{
     color: #0077b5;
     font-size: 30px;
     }
     .sd-content a.nc-twitter-circled{
     color: #00acee;
     font-size: 30px;
     }
     .sd-content a.nc-fa-envelope-square{
     color: #034193 ;
     font-size: 30px;
     }  
     .sd-content a.nc-fa-print{
     color: #000 ;
     font-size: 30px;
     }                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
     .sd-content a hover {
     }
     .sd-content i {
      margin: -4px;
     }
     #searchsubmit {
      font-size: 1em;
      border-radius: 3px;
      font-family: 'Oswald';
      text-transform: uppercase;
      letter-spacing: 2px;
      border-style: solid;
      border-width: 0;
      font-weight: 500;
    }
</style>

<meta name="google-site-verification" content="OD6S3RPM-cQOknAs1uXmBRvRJyh28rwkOoqdes47ZUE">
</head>
<body class="single single-post postid-572367971 single-format-standard full-width custom-background-empty">
    <!-- Google Tag Manager (noscript) -->
    <noscript>
      <iframe src="https://www.googletagmanager.com/ns.html?id=GTM-T8Z9VLF" height="0" width="0" style="display:none;visibility:hidden"></iframe>
    </noscript>
    <!-- End Google Tag Manager (noscript) -->
    <script type="text/javascript"> 
<!-- 
var bb=new Image();var _ti=910;var _q="";var na=(navigator.appName=="Netscape");var ns=(navigator.appName.substring(0,9)=="Microsoft");var _qDate=new Date();var _r=(document.referrer.indexOf(getdomain(location))>-1?"":document.referrer);_q+="&5="+parseInt(_qDate.getTimezoneOffset());_q+="&35="+parseInt(_qDate.toString().indexOf("aylight")>-1?1:0);_q+="&6=572367971";_q+="&7=3262841";_q+="&8="+encodeURIComponent(document.location);_q+="&9="+encodeURIComponent(_r);_q+="&10="+encodeURIComponent(document.title);_q+="&11="+encodeURIComponent(navigator.userAgent);_q+="&12="+encodeURIComponent((na?navigator.language:navigator.userLanguage));_q+="&13="+((navigator.javaEnabled()?'1':'0'));if(document.cookie.indexOf("cc")==-1)document.cookie="cc=t;";_q+="&15="+((document.cookie.indexOf("cc")==-1)?"0":"1");_q+="&16="+encodeURIComponent((screen.width+'x'+screen.height));_q+="&17="+encodeURIComponent(((ns)?screen.colorDepth:screen.pixelDepth));_q+="&18="+encodeURIComponent(Math.random());_q+="&19="+_ti;bb.src="https://s.clickability.com/s?"+_q;
function setonclicks(a,b){var i=0;var retval=true;while(document.links[i]!=a){i++;}if(b.li[i])retval=b.li[i].oldonclick();bye(a);return retval;}
function newonld(){if(hasonload)oldonld();lnks=new Object();var sze=document.links.length;lnks.li=new Array(sze);for (var i=0; i<sze; i++){if(document.links[i].onclick){lnks.li[i]=document.links[i];lnks.li[i].oldonclick=document.links[i].onclick;}eval("document.links[i].onclick=function(){return setonclicks(this,lnks);}");}}function bye(a){if(a.href.toLowerCase().indexOf('http')!=0)return true;if(getdomain(location)==getdomain(a))return true;if(a.href.toLowerCase().indexOf('http')!=0)return true;var _qc="https://s.clickability.com/s?19=912";_qc+="&6=572367971";_qc+="&7=3262841";_qc+="&18="+encodeURIComponent(Math.random());_qc+="&100="+a.href;_qc+="&101="+encodeURIComponent(a.text);var cc=new Image();if(na){cc.src=_qc;pc(100);}else cc.src=_qc;return true;}function pc(a){d = new Date(); while (1){m =new Date(); df = m-d;if( df > a ) {break;}}}function getdomain(a){var i=a.host.indexOf(":");return (i>=0)?a.host.substring(0,i):a.host;}if(self['setupalready']){var dosetup = false;alert('There are two $imware.tracker calls on this page. Please alert Client Services');}else{var dosetup = true;var hasonload=false;}if(dosetup && ((window.screen)||((new Array()).toSource)||((new Array()).shift&&ns))&&(navigator.userAgent.indexOf('Mac')<0)){if(window.onload){oldonld=window.onload;hasonload=true;}window.onload=newonld;var setupalready = true;}//-->
</script><noscript>
<img alt="Clickability tracking pixel" width="1" height="1" src="https://s.clickability.com/s?19=990&amp;14=0&amp;6=572367971&amp;7=3262841&amp;25=0&amp;18=0.28824373668595926">
</noscript>

<div class="main-body-container" data-equalizer>    
<div class="nav_container">
	<a class="skip-link screen-reader-text" href="#content">Skip to content</a>  
        <div class="nav_wrap row ">
        	<div> <!-- add sticky here if needed -->
        	  <div>
                    <nav class="top-bar" data-topbar data-options="scrolltop:false;mobile_show_parent_link:false;">                  
                        <ul class="title-area">
	                        <li class="mofo-logo">
			                    <a href="https://www.mofo.com" title="Morrison & Foerster" target="_blank">
						<img src="https://media2.mofo.com/images/morrison-foerster-blog-logo.png" alt="logo">
			                    </a>
			                </li>
                            <li class="name">
                                <div class="header-title">
                                	<a href="index.html" title="MoFo Life Sciences" rel="home">
                                	                                	MoFo Life Sciences
                                	                                	</a>
                                </div>
                                                                <div class="header-subtitle">
                               		<span class="pms-7702c">Because No One is Immune to the Law</span>
                                </div>
                                                            </li>							
                            <!-- Remove the class "menu-icon" to get rid of menu icon. Take out "Menu" to just have icon alone -->
                                                    </ul>
</nav>
</div><!-- contain-to-grid sticky -->                
</div><!-- .row -->
</div>        
</div>
<!-- end .nav_container -->  


<div class="topnav" id="myTopnav">

<a href="index.html">Home</a>



<div class="divider"></div>
<div class="dropdown">

    <button class="dropbtn active">Topics 
     <i class="fa fa-caret-down"></i>
    </button>
    <div class="dropdown-content">

	
		 	<a href="topics_20.html">AI + Robotics</a>
		 	<a href="topics_5.html">Agtech</a>
		 	<a href="topics.html">Announcements</a>
		 	<a href="topics_2.html">Antitrust</a>
		 	<a href="topics_13.html">Asia</a>
		 	<a href="topics_9.html">Bioinformatics</a>
		 	<a href="topics_27.html">Biotech</a>
		 	<a href="topics_30.html">Blockchain</a>
		 	<a href="topics_6.html">CFIUS</a>
		 	<a href="topics_4.html">COVID-19</a>
		 	<a href="topics_16.html">Corporate + Venture Capital</a>
		 	<a href="topics_10.html">Data Analytics</a>
		 	<a href="topics_11.html">Digital Health</a>
		 	<a href="topics_23.html">Employment</a>
		 	<a href="topics_31.html">European Union</a>
		 	<a href="topics_18.html">FDA</a>
		 	<a href="topics_12.html">Financing</a>
		 	<a href="topics_29.html">Global</a>
		 	<a href="topics_21.html">Healthcare</a>
		 	<a href="topics_24.html">Intellectual Property</a>
		 	<a href="topics_3.html">Licensing + Commercial</a>
		 	<a href="topics_15.html">Litigation</a>
		 	<a href="topics_25.html">Medical Devices + Diagnostics</a>
		 	<a href="topics_17.html">Pharma</a>
		 	<a href="topics_19.html">Privacy + Data Security</a>
		 	<a href="topics_14.html">Product Liability + Class Action</a>
		 	<a href="topics_7.html">Rare Disease</a>
		 	<a href="topics_1.html">Regulatory</a>
		 	<a href="topics_26.html">Startup</a>
		 	<a href="topics_28.html">United Kingdom</a>
		 	<a href="topics_22.html">United States</a>
    </div>
  </div> 


<div class="divider"></div>
<a href="editors.html" class>Editors</a>


<div class="divider"></div>
<a href="about.html" class>About</a>


<div class="divider"></div>
<a href="javascript:void(0);" onclick="openSubscribeModal()" class>Subscribe</a>




<a href="javascript:void(0);" style="font-size:15px;" class="icon" onclick="myFunction()">&#9776;</a>
</div>
    
    
    
    
    


<script>
function printPage() {
  window.print();
}
</script>



<div class="content_container">
    <section class="content_wrap row" role="document">
        <div id="content" class="medium-8 large-8 columns" role="main">
            <article id="post-572367971" class="post-572367971 post type-post status-publish format-standard has-post-thumbnail hentry category-foreign-corrupt-practices-act">
                <header class="entry-header">
                    <div class="row blog-header">
                        <div class="columns medium-7 rockwell pms-7702c">
                            <em>September 9, 2020</em>
                            - <a href="topics_27.html" rel="category tag">Biotech</a>, <a href="topics_18.html" rel="category tag">FDA</a>, <a href="topics_21.html" rel="category tag">Healthcare</a>, <a href="topics_24.html" rel="category tag">Intellectual Property</a>, <a href="topics_17.html" rel="category tag">Pharma</a>, <a href="topics_22.html" rel="category tag">United States</a>
                        </div>
                        <div class="columns medium-5 social-jet">
                            <div class="sharedaddy sd-sharing-enabled">
                                <div class="robots-nocontent sd-block sd-social sd-social-icon sd-sharing">
                                    <h3 class="sd-title">Share This</h3>
                                            <div class="sd-content">
                                                <a title="Share on Facebook" class="nc-facebook-circled" href="unsupportedbrowser.html" target="_blank" onclick="javascript:window.open(this.href, '', 'menubar=no,toolbar=no,resizable=yes,scrollbars=yes,height=350,width=600');return false;" rel="nofollow">
                                                    <i class="fab fa-facebook-square"></i>
                                                                                                    </a>
                                                <a href="https://www.linkedin.com/shareArticle?mini=true&amp;url=https://lifesciences.mofo.com/topics/pediatric-exclusivity-for-biologics.html&amp;title=Pediatric Exclusivity for Biologics&amp;summary=The U.S. Food and Drug Administrations six-month pediatric exclusivity rules that apply to drugs also largely apply to biologics (albeit with certain distinctions), which may become a valuable life cycle management strategy for biopharmaceutical companies (hereinafter Sponsors) in addition to patent exclusionary rights.

At the&amp;source=LinkedIn" onclick="javascript:window.open(this.href, '', 'menubar=no,toolbar=no,resizable=yes,scrollbars=yes,height=350,width=600');return false;" rel="nofollow" class="nc-linkedin-circled" target="_blank" title="Share on LinkedIn">
                                                    <i class="fab fa-linkedin"></i>
                                                                                                    </a>
                                                <a href="share_175.html" onclick="javascript:window.open(this.href, '', 'menubar=no,toolbar=no,resizable=yes,scrollbars=yes,height=350,width=600');return false;" rel="nofollow" target="_blank" class="nc-twitter-circled" title="Share on Twitter">
                                                    <i class="fab fa-twitter-square"></i>
                                                                                                    </a>
                                                <a href="mailto:recipient@domain.com?subject=MoFo Life Sciences&amp;body=Pediatric Exclusivity for Biologics - https://lifesciences.mofo.com/topics/pediatric-exclusivity-for-biologics.html" rel="nofollow" class="nc-fa-envelope-square" title="Email this page">
                                                  <i class="fas fa-envelope-square"></i>
                                                </a>
                                                <a href="#" onclick="printPage()" rel="nofollow" class="nc-fa-print" title="Print this page">
                                                  <i class="fas fa-print"></i>
                                                </a>
                                            </div>
                                </div>
                            </div>
                        </div>
                    </div>
                    <h1 class="entry-title">
                        Pediatric Exclusivity for Biologics</h1>
                </header>
                <!-- .entry-header -->
                <div class="entry-meta">
                    <div class="blog-author-meta subheader">			
                                                

                                                                    </div>
                </div>
                <div class="entry-content">
                                    <img width="300" class="alignright" src="https://media2.mofo.com/images/mofolifesciences-intellectual-property.jpg">
                                        <p>The U.S. Food and Drug Administration&rsquo;s six-month pediatric exclusivity rules that apply to drugs also largely apply to biologics (albeit with certain distinctions), which may become a valuable life cycle management strategy for biopharmaceutical companies (hereinafter &ldquo;Sponsors&rdquo;) in addition to patent exclusionary rights.</p>
<p>At the outset, it is important to recognize that the patent term of a biologic product is distinct from the FDA&rsquo;s regulatory market exclusivity period for the same product; these two public policies are governed by entirely separate laws and regulations. Patent term and the FDA&rsquo;s exclusivity programs run concurrently and in parallel. As such, pediatric exclusivities (or other FDA exclusivities) do not formally extend the term of any patent rights. However, both of these legal frameworks have the same effect of extending the biologic product&rsquo;s market monopoly and preventing competitors from introducing biosimilar products into the marketplace. In the event that certain patents rights are invalidated prior to the expiration of the full patent term, FDA exclusivities provide an additional safeguard against competitors seeking to enter the market. Thus, Sponsors should consider using both patent rights and FDA exclusivities to recoup research and development investments.</p>
<p>Biologics are eligible to participate in the FDA&rsquo;s pediatric exclusivity program.[i] Under Section 351 of the Public Health Service Act, in order to receive six months of pediatric exclusivity in addition to the 12-year exclusivity period granted under the Biologics Price Competition and Innovation Act,[ii] the FDA must issue a Written Request for the Sponsor to conduct specific pediatric studies for a given biological product.[iii] The Sponsor may choose (but is not required) to conduct the pediatric studies outlined in the Written Request, at its own expense, in exchange for an additional six months of exclusivity for its biological product. The exclusivity grant is based on whether the applicant complied with the terms of the Written Request and is not conditioned on approval of a pediatric indication.[iv] Any unauthorized deviation from the Written Request may result in non-compliance and can jeopardize the Sponsor&rsquo;s ability to earn pediatric exclusivity. The FDA maintains discretion over issuing Written Requests for pediatric studies, and thereby controls the Sponsor&rsquo;s ability to obtain multiple pediatric exclusivities. The FDA may issue multiple Written Requests, which are each eligible for an additional six-month exclusivity period, provided that the Sponsor appropriately complies with each Written Request.[v] Examples of previous Written Requests for biologics can be found on the FDA&rsquo;s <a target="_blank" href="https://www.fda.gov/drugs/development-resources/list-determinations-including-written-request">List of Determinations Including Written Request</a> web page (<i>see, e.g.</i>,<i> </i>ipilimumab and tocilizumab). It appears that the FDA has not yet issued multiple Written Requests for a single biologic. In fact, it appears rare for the FDA to issue multiple Written Requests for the same drug.</p>
<p>&nbsp;</p>
<p>In a previous <a target="_blank" href="https://www.fda.gov/media/72029/download">Guidance</a>, the FDA explained that a Sponsor of a new drug under Section 505A of the Federal Food, Drug, and Cosmetic Act (FDCA) may submit a detailed proposal to the FDA for a Written Request, which is equally applicable to the holder of an approved Biologics License Application under Section 351 of the Public Health Service Act.[vi] The proposal for a Written Request should substantially follow the template that the FDA has previously used for a Written Request (<i>see, e.g.</i>,<i> </i><a target="_blank" href="https://www.fda.gov/media/106997/download">ipilimumab</a> and <a target="_blank" href="https://www.fda.gov/media/115367/download">tocilizumab</a>). The proposal should contain sufficient information to execute the studies such as the objective of the study, trial design, number and kinds of patients and other relevant patient characteristics, inclusion and exclusion criteria for the study, drug dosing for the treatment arm, statistical information for analyzing the results, and other pertinent information.[vii] The FDA will then evaluate the proposal and decide whether to issue a formal Written Request based on the information submitted. In addition, the FDA maintains a <a target="_blank" href="https://www.fda.gov/drugs/development-resources/qualifying-pediatric-exclusivity-under-section-505a-federal-food-drug-and-cosmetic-act-frequently">FAQ web page</a> dedicated to qualifying for pediatric exclusivity under Section 505A of the FDCA. To qualify for pediatric exclusivity, the pediatric studies conducted to satisfy the requirements of the Pediatric Research Equity Act (PREA) must also satisfy all of the requirements for pediatric exclusivity under Section 505A of the FDCA.[viii]</p>
<p>Fulfilling the Written Request for pediatric exclusivity is separate from meeting the Sponsor&rsquo;s PREA obligations or any other requirements to perform phase 4 post-market surveillance studies.[ix] PREA requires that all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients, unless this requirement is waived, deferred, or inapplicable.[x] In terms of scope, PREA is more limited and requires a pediatric assessment of those indications included in the pending biologics license application (BLA), which addresses the safety and effectiveness of the claimed indications with respect to the drug or biological product. The FDA&rsquo;s authority to issue a Written Request for pediatric exclusivity extends to the use of an active moiety for <i>all indications</i> that occur in the pediatric population, regardless of whether the indications have been previously approved in adults or approval for those indications is being sought in adults.[xi] The FDA has previously advised that an applicant seeking to qualify for pediatric exclusivity should obtain a Written Request for studies from FDA before submitting the pediatric studies to satisfy PREA.<sup><sup>[xii]</sup></sup><i>&nbsp;</i></p>
<p>&nbsp;</p>
<p><br clear="all"></p>
<hr width="33%" size="1">
<p>[i] <i>See</i> 42 U.S.C. &sect; 262(m) (Section 351 of the Public Health Service Act). Notice that under &sect; 262(m)(1), the rules for submitting pediatric studies are the same for both drugs and biologics under &sect; 505A of the Federal Food, Drug, and Cosmetic Act (FDCA) (codified as 21 U.S.C. &sect; 355a). More precisely, &sect; 262(m)(1) carves out the exclusivity benefits in &sect;&sect; 505A (b)-(c) for drugs, which are then re-inserted as &sect;&sect; 262(m)(2)-(3) as applicable to biologics given the different exclusivity periods.</p>
<p>[ii] <i>See </i>42 U.S.C. &sect; 262(k).<i>&nbsp;</i></p>
<p>[iii] <i>See</i> 42 U.S.C. &sect; 262(m) (Section 351 of the Public Health Service Act). Under both &sect;&sect; 262(m)(2) and m(3), the Secretary makes a written request to the applicant to perform additional pediatric studies, and the applicant accepts that request (at its own expense), the applicant is rewarded another six months of exclusivity. Note that under 21 U.S.C &sect; 355a(h) (carried over into 42 U.S.C. &sect; 262(m)(1) for biologics), pediatric exclusivity shall only be granted for a study or studies that are the subject of a Written Request from the FDA and prior to nine months from expiration.</p>
<p>[iv] <i>See </i><a target="_blank" href="https://www.fda.gov/drugs/development-resources/qualifying-pediatric-exclusivity-under-section-505a-federal-food-drug-and-cosmetic-act-frequently">https://www.fda.gov/drugs/development-resources/qualifying-pediatric-exclusivity-under-section-505a-federal-food-drug-and-cosmetic-act-frequently</a>.</p>
<p>[v] <i>See </i><a target="_blank" href="https://www.fda.gov/media/72029/download">Guidance for Industry, Qualifying for Pediatric Exclusivity Under Section 505(A) of the Federal Food, Drug, and Cosmetic Act (June 1998, revised Sept. 1999</a><span style="text-decoration: underline;">)</span>.<i>&nbsp;</i></p>
<p>[vi] <i>See id. </i>(listing specific requirements for a Proposed Pediatric Study Request).</p>
<p>[vii] <i>See id.</i></p>
<p>[viii] <i>See</i> Sections 505A(d) and 505A(h) of the FDCA (codified as 21 U.S.C. &sect;&sect; 355a(d) and (h), respectively).</p>
<p>[ix] <i>See </i>Section 505B of the FDCA (codified as 21 U.S.C. &sect; 355c). PREA also authorized the FDA to waive the required assessments when the drug or biological product (1) does not represent a meaningful therapeutic benefit over existing therapies for pediatric patients and (2) is not likely to be used in a substantial number of pediatric patients.</p>
<p>[x] <i>See id.</i></p>
<p>[xi] <i>See</i> Section 505A(a) of the FDCA, codified as 21 U.S.C. &sect; 355a(b)(1).</p>
<p>[xii] <a target="_blank" href="https://www.fda.gov/regulatory-information/search-fda-guidance-documents/how-comply-pediatric-research-equity-act"><i>See </i>Draft Guidance for Industry: How to Comply with the Pediatric Research Equity Act (Sept. 2005)</a>.</p>
                        <div class="sharedaddy sd-sharing-enabled">
                            <div class="robots-nocontent sd-block sd-social sd-social-icon sd-sharing">
                                <h3 class="sd-title">Share This</h3>
                                        <div class="sd-content">
                                                <a title="Share on Facebook" class="nc-facebook-circled" href="unsupportedbrowser.html" target="_blank" onclick="javascript:window.open(this.href, '', 'menubar=no,toolbar=no,resizable=yes,scrollbars=yes,height=350,width=600');return false;" rel="nofollow">
                                                    <i class="fab fa-facebook-square"></i>
                                                                                                    </a>
                                                <a href="https://www.linkedin.com/shareArticle?mini=true&amp;url=https://lifesciences.mofo.com/topics/pediatric-exclusivity-for-biologics.html&amp;title=Pediatric Exclusivity for Biologics&amp;summary=The U.S. Food and Drug Administrations six-month pediatric exclusivity rules that apply to drugs also largely apply to biologics (albeit with certain distinctions), which may become a valuable life cycle management strategy for biopharmaceutical companies (hereinafter Sponsors) in addition to patent exclusionary rights.

At the&amp;source=LinkedIn" onclick="javascript:window.open(this.href, '', 'menubar=no,toolbar=no,resizable=yes,scrollbars=yes,height=350,width=600');return false;" rel="nofollow" class="nc-linkedin-circled" target="_blank" title="Share on LinkedIn">
                                                    <i class="fab fa-linkedin"></i>
                                                                                                    </a>
                                                <a href="share_175.html" onclick="javascript:window.open(this.href, '', 'menubar=no,toolbar=no,resizable=yes,scrollbars=yes,height=350,width=600');return false;" rel="nofollow" target="_blank" class="nc-twitter-circled" title="Share on Twitter">
                                                    <i class="fab fa-twitter-square"></i>
                                                                                                    </a>
                                                <a href="mailto:recipient@domain.com?subject=MoFo Life Sciences&amp;body=Pediatric Exclusivity for Biologics - https://lifesciences.mofo.com/topics/pediatric-exclusivity-for-biologics.html" rel="nofollow" class="nc-fa-envelope-square" title="Email this page">
                                                  <i class="fas fa-envelope-square"></i>
                                                </a>
                                                <a href="#" onclick="printPage()" rel="nofollow" class="nc-fa-print" title="Print this page">
                                                  <i class="fas fa-print"></i>
                                                </a>
                                        
                                        </div>
                            </div>
                        </div>
                        <!-- .entry-content -->
                        <footer class="entry-meta">
                            <div class="entry-meta-footer">
                            </div>
                            <!-- end .entry-meta-footer -->
                        </footer>
                        <!-- .entry-meta -->
</div></article>
<!-- #post -->
                </div>
                <!-- #content -->
                <div id="secondary" class="medium-4 large-4 columns widget-area data-equalizer-watch" role="complementary">
                                        





<aside id="black-studio-tinymce-3" class="widget widget_black_studio_tinymce">
    <div class="textwidget">
        <div class="gray-sidebar">
            <h5>Stay Connected </h5>
                                        <a title="Connect via LinkedIn" class="nc-linkedin-circled" href="https://www.linkedin.com/company/morrison-&amp;-foerster-llp" target="_blank">
                        <i class="icon-linkedin-circled footer-icons black85"></i>
                    </a>
                                        <a title="Connect via Twitter" class="nc-twitter-circled" href="https://twitter.com/MoFoLLP" target="_blank">
                        <i class="icon-twitter-circled footer-icons black85"></i>
                    </a>
                                        <a title="Connect via RSS" class="nc-rss" href="rss" target="_blank">
                        <i class="icon-rss footer-icons black85"></i>
                    </a>
                            </div>
    </div>
</aside>
<aside id="search-2" class="widget widget_search">
    <form role="search" method="get" id="searchform" action="/search/">
        <div class="row collapse">
            <div class="medium-12 large-12 columns">
                <input type="text" value name="s" id="s">
                    <div class="search-icon">
                        <i class="icon-search footer-icons pms-7702c"></i>
                    </div>
                    <input type="submit" id="searchsubmit" value="Search" class="search-btn">
                    </div>
</div>
</form>
</aside>
<aside id="categories-2" class="widget widget_categories">
    <h6 class="widget-title">Topics</h6>
            <label class="screen-reader-text" for="cat">Topics</label>
            <select name="cat" id="cat" class="postform">
                <option value="-1">Topics</option>
                                                                                                                                                <option class="level-0" value="1457511">AI + Robotics</option>
                                                                                                <option class="level-0" value="1457521">Agtech</option>
                                                                                                <option class="level-0" value="1457691">Announcements</option>
                                                                                                <option class="level-0" value="1462201">Antitrust</option>
                                                                                                <option class="level-0" value="1457531">Asia</option>
                                                                                                <option class="level-0" value="1468521">Bioinformatics</option>
                                                                                                <option class="level-0" value="1456751">Biotech</option>
                                                                                                <option class="level-0" value="1458171">Blockchain</option>
                                                                                                <option class="level-0" value="1458511">CFIUS</option>
                                                                                                <option class="level-0" value="1462211">COVID-19</option>
                                                                                                <option class="level-0" value="1457541">Corporate + Venture Capital</option>
                                                                                                <option class="level-0" value="1458861">Data Analytics</option>
                                                                                                <option class="level-0" value="1465651">Digital Health</option>
                                                                                                <option class="level-0" value="1458521">Employment</option>
                                                                                                <option class="level-0" value="1457551">European Union</option>
                                                                                                <option class="level-0" value="1459381">FDA</option>
                                                                                                <option class="level-0" value="1457561">Financing</option>
                                                                                                <option class="level-0" value="1459511">Global</option>
                                                                                                <option class="level-0" value="1459951">Healthcare</option>
                                                                                                <option class="level-0" value="1457581">Intellectual Property</option>
                                                                                                <option class="level-0" value="1457591">Licensing + Commercial</option>
                                                                                                <option class="level-0" value="1457601">Litigation</option>
                                                                                                <option class="level-0" value="1459061">Medical Devices + Diagnostics</option>
                                                                                                <option class="level-0" value="1457631">Pharma</option>
                                                                                                <option class="level-0" value="1457641">Privacy + Data Security</option>
                                                                                                <option class="level-0" value="1457651">Product Liability + Class Action</option>
                                                                                                <option class="level-0" value="1465361">Rare Disease</option>
                                                                                                <option class="level-0" value="1459071">Regulatory</option>
                                                                                                <option class="level-0" value="1459521">Startup</option>
                                                                                                <option class="level-0" value="1462611">United Kingdom</option>
                                                                                                <option class="level-0" value="1457671">United States</option>
                                                            </select>
            <script type="text/javascript">
                /* <![CDATA[ */
                (function() {
                var dropdown = document.getElementById( "cat" );
                function onCatChange() {
                if ( dropdown.options[ dropdown.selectedIndex ].value > 0 ) {
                location.href = "/topics/?c=" + dropdown.options[ dropdown.selectedIndex ].value;
                }
                }
                dropdown.onchange = onCatChange;
                })();
                /* ]]> */
            </script>
</aside>
<aside class="widget widget_recent_entries">
    <h6 class="widget-title">Recent Posts</h6>
            <ul>
                                                    <li>
                        <a href="eu-in-vitro-diagnostic-regulation-entered-into-force-part-3-of-3.html">EU: IN VITRO DIAGNOSTIC REGULATION ENTERED INTO FORCE (PART 3 OF 3)</a>
                    </li>
                                                                    <li>
                        <a href="fda-will-once-again-accept-pre-submissions-for-all-in-vitro-diagnostic-tests.html">FDA Will Once Again Accept Pre-Submissions for All In Vitro Diagnostic Tests</a>
                    </li>
                                                                    <li>
                        <a href="eu-in-vitro-diagnostic-regulation-entered-into-force--part-2-of-3.html">EU: IN VITRO DIAGNOSTIC REGULATION ENTERED INTO FORCE  (PART 2 OF 3) </a>
                    </li>
                                                                    <li>
                        <a href="eu-in-vitro-diagnostic-regulation-entered-into-force--part-1-of-3.html">EU: IN VITRO DIAGNOSTIC REGULATION ENTERED INTO FORCE  (PART 1 OF 3) </a>
                    </li>
                                                                    <li>
                        <a href="senators-call-for-report-on-state-of-psychedelic-research.html">Senators Call for Report on State of Psychedelic Research</a>
                    </li>
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            </ul>
</aside>
<aside id="black-studio-tinymce-6" class="widget widget_black_studio_tinymce">
     <style>

address {
  font-style: normal;
  margin-bottom: 14px;
  margin-left: 10px;
}

address .contact  {
  display: block;
  
}

address .email a:hover {
  color: #0078a0;
}

.location, .attorney, .email {
  display: block;

}

address .email a {
color: #5e5f61;
}

.location {
  font-weight: 900;
  font-family: 'Oswald', sans-serif;
  text-transform: uppercase;
}

.contact-title {
  font-family: 'Oswald', sans-serif;
  font-size: .825em;
  background-color: #eeeeee;
  padding: .8em;
  letter-spacing: 2px;
  text-transform: uppercase;
  margin-bottom: 10px;
  display: block;
  font-weight: 900;
}

</style>




</aside>
                </div>
                <!-- #secondary -->
</section>
<!-- end .content-wrap -->
        </div>
        <!-- end .content_container -->
        <div style="display:none;" id="dialog-message" title="Email Disclaimer">
	<p>Unsolicited e-mails and information sent to Morrison &amp; Foerster will not be considered confidential, may be disclosed to others pursuant to our Privacy Policy, may not receive a response, and do not create an attorney-client relationship with Morrison &amp; Foerster. If you are not already a client of Morrison &amp; Foerster, do not include any confidential information in this message. Also, please note that our attorneys do not seek to practice law in any jurisdiction in which they are not properly authorized to do so.</p>
</div>
<div class="footer_container">
    <footer class="footer_wrap row" role="contentinfo">
        <div id="footer" class="row" role="contentinfo">
            <div class="columns medium-12 footer-nav-wrapper">
                <div class="footer-nav">
                    <ul>
                                                <li class="divider"></li>
                        <li id="menu-item-3395" class="menu-item menu-item-footer menu-item-terms-of-use">
                            <a target="_blank" href="https://www.mofo.com/about/terms-notices.html">Terms of Use</a>
                        </li>
                                                <li class="divider"></li>
                        <li id="menu-item-3395" class="menu-item menu-item-footer menu-item-cookies">
                            <a target="_blank" href="https://www.mofo.com/about/cookies.html">Cookies</a>
                        </li>
                                                <li class="divider"></li>
                        <li id="menu-item-3395" class="menu-item menu-item-footer menu-item-privacy-policy">
                            <a target="_blank" href="https://www.mofo.com/about/privacy-policy.html">Privacy Policy</a>
                        </li>
                                                <li class="divider"></li>
                        <li id="menu-item-3395" class="menu-item menu-item-footer menu-item-disclaimer">
                            <a target="_blank" href="https://www.mofo.com/special-content/blog-disclaimer/">Disclaimer</a>
                        </li>
                                                <li class="divider"></li>
                        <li id="menu-item-3395" class="menu-item menu-item-footer menu-item-attorney-advertising">
                            <a target="_blank" href="https://www.mofo.com/about/attorney-advertising.html">Attorney Advertising</a>
                        </li>
                        </ul></div>
                </div>
                <div class="columns medium-12 text-center">
                    <p class="copyright">&copy;1996-2022 Morrison &amp; Foerster LLP. <span class="show-for-small"><br></span>All Rights Reserved.</p>
                </div>
                <div class="medium-2 medium-centered columns">
                                                            <a title="Connect via LinkedIn" class="nc-linkedin" href="https://www.linkedin.com/company/morrison-&amp;-foerster-llp" target="_blank">
                        <i class="icon-linkedin-circled footer-icons pms-7702c"></i>
                    </a>
                                                            <a title="Connect via Twitter" class="nc-twitter" href="https://twitter.com/MoFoLLP" target="_blank">
                        <i class="icon-twitter-circled footer-icons pms-7702c"></i>
                    </a>
                                                            <a title="Connect via RSS" class="nc-rss" href="rss" target="_blank">
                        <i class="icon-rss footer-icons pms-7702c"></i>
                    </a>
                                    </div>
                                            </div>
</footer>
<!-- .row -->
</div>
<!-- end #footer_container -->
<div id="backtotop" class="hvr-fade">
    <span class="genericon genericon-collapse"></span>
</div>
<!-- #backtotop -->

</div>
     <div class="textwidget">
        <div id="subscribe-modal" class="reveal-modal" data-reveal aria-labelledby="subscribe-modal" aria-hidden="true" role="dialog">
            <aside class="widget widget_black_studio_tinymce">
                <div class="textwidget newsletter_subscribe">
                    <div>
                        <h5>Subscribe</h5>
                                <p>Never miss a post from MoFo Life Sciences. Enter your email below to stay up-to-date.</p>
                    </div>
                </div>
                            </aside>
            <p>
                <div class="resultLabel"></div>
                <div class="widget_wysija_cont shortcode_wysija newsletter_subscribe">
                                   <iframe src="https://www2.mofo.com/l/323401/2020-09-03/621wk" width="100%" height="450" type="text/html" frameborder="0" allowTransparency="true" style="border: 0"></iframe>
                                                </div>
                    <a class="close-reveal-modal" onClick="closeSubscriptionModal()" aria-label="Close"></a>
</p></div>
</div>



<script>
  (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
  (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
  m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
  })(window,document,'script','https://www.google-analytics.com/analytics.js','ga');
  ga('create', 'UA-12456654-15', 'auto');   ga('send', 'pageview');
</script>

<script type="text/javascript"> 
/*<![CDATA[*/ 
(function() { 
var sz = document.createElement('script'); sz.type = 'text/javascript'; sz.async = true; 
sz.src = '//siteimproveanalytics.com/js/siteanalyze_59840.js'; 
var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(sz, s); 
})(); 
/*]]>*/ 
</script>




<script>
  function myFunction() {
    var x = document.getElementById("myTopnav");
    if (x.className === "topnav") {
      x.className += " responsive";
    } else {
      x.className = "topnav";
    }
  }
  </script>
  
  
  <script>
  

function openSubscribeModal() {
console.log('openSubscribeModal')
  var m = document.getElementById('subscribe-modal');
  m.style.visibility = 'visible';
  m.style.display = 'block';
  }
  
  function closeSubscriptionModal() {
    var m = document.getElementById('subscribe-modal');
  m.style.visibility = 'hidden';
  m.style.display = 'none';
  }

  </script>
  

</body>
</html>